ArticleArXiv2021
Identification and Development of Therapeutics for COVID-19.
Open access · greenAbstract readPreprint
In one paragraph
Article in ArXiv, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
24 authors at 12 institutions in 3 countries.
Halie M RandoDepartment of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America; Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora, Colorado, United States of America; Center for Health AI, University of Colorado School of Medicine, Aurora, Colorado, United States of America · Funded by the Gordon and Betty Moore Foundation (GBMF 4552).ORCID 0000-0001-7688-1770
Nils WellhausenDepartment of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.ORCID 0000-0001-8955-7582
Soumita GhoshInstitute of Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.ORCID 0000-0002-2783-2750
Alexandra J LeeDepartment of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America · Funded by the Gordon and Betty Moore Foundation (GBMF 4552).ORCID 0000-0002-0208-3730
Anna Ada DattoliDepartment of Systems Pharmacology & Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0003-1462-831X
Fengling HuDepartment of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.ORCID 0000-0003-1081-5038
James Brian ByrdUniversity of Michigan School of Medicine, Ann Arbor, Michigan, United States of America · Funded by NIH K23HL128909; FastGrants.ORCID 0000-0002-0509-3520
Diane N RafizadehPerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America; Department of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania, United States of AmericaFunded by NIH Medical Scientist Training Program T32 GM07170.ORCID 0000-0002-2838-067X
Ronan LordanInstitute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-5158, USA.ORCID 0000-0001-9668-3368
Yanjun QiDepartment of Computer Science, University of Virginia, Charlottesville, VA, United States of America.ORCID 0000-0002-5796-7453
Yuchen SunDepartment of Computer Science, University of Virginia, Charlottesville, VA, United States of America.
Christian BruefferDepartment of Clinical Sciences, Lund University, Lund, Sweden.ORCID 0000-0002-3826-0989
Jeffrey M FieldDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0001-7161-7284
Marouen Ben GuebilaDepartment of Biostatistics, Harvard School of Public Health, Boston, Massachusetts, United States of America.ORCID 0000-0001-5934-966X
Nafisa M JadavjiBiomedical Science, Midwestern University, Glendale, AZ, United States of America; Department of Neuroscience, Carleton University, Ottawa, Ontario, Canada · Funded by the American Heart Association (20AIREA35050015).ORCID 0000-0002-3557-7307
Ashwin N SkellyPerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America; Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, United States of America · Funded by NIH Medical Scientist Training Program T32 GM07170.ORCID 0000-0002-1565-3376
Bharath RamsundarThe DeepChem Project, https://deepchem.io/.ORCID 0000-0001-8450-4262
Jinhui WangPerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.ORCID 0000-0002-5796-8130
Rishi Raj GoelInstitute for Immunology, University of Pennsylvania, Philadelphia, PA, United States of America.ORCID 0000-0003-1715-5191
YoSon ParkDepartment of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America · Funded by NHGRI R01 HG10067.ORCID 0000-0002-0465-4744
COVID-19 Review Consortium
Simina M BocaInnovation Center for Biomedical Informatics, Georgetown University Medical Center, Washington, District of Columbia, United States of America; Early Biometrics & Statistical Innovation, Data Science & Artificial Intelligence, R & D, AstraZeneca, Gaithersburg, Maryland, United States of America.ORCID 0000-0002-1400-3398
Anthony GitterDepartment of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, Wisconsin, United States of America; Morgridge Institute for Research, Madison, Wisconsin, United States of America · Funded by John W. and Jeanne M. Rowe Center for Research in Virology.ORCID 0000-0002-5324-9833
Casey S GreeneDepartment of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America; Childhood Cancer Data Lab, Alex's Lemonade Stand Foundation, Philadelphia, Pennsylvania, United States of America; Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Aurora, Colorado, United States of America; Center for Health AI, University of Colorado School of Medicine, Aurora, Colorado, United States of America · Funded by the Gordon and Betty Moore Foundation (GBMF 4552); the National Human Genome Research Institute (R01 HG010067).ORCID 0000-0001-8713-9213
Translational Therapeutics (United States) · USUniversity of Pennsylvania · USGeorgetown University · USUniversity of Virginia · USGordon and Betty Moore Foundation · USHarvard University · USLund University · SEMidwestern University · USMorgridge Institute for Research · USUniversity City Science Center · USUniversity of Colorado Denver · USUniversity of Michigan · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
After emerging in China in late 2019, the novel coronavirus SARS-CoV-2 spread worldwide and as of mid-2021 remains a significant threat globally. Only a few coronaviruses are known to infect humans, and only two cause infections similar in severity to SARS-CoV-2:
Identifiers
PMID
33688554PMC
PMC7941644OpenAlex
W4287284766What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.